<code id='167A4925F5'></code><style id='167A4925F5'></style>
    • <acronym id='167A4925F5'></acronym>
      <center id='167A4925F5'><center id='167A4925F5'><tfoot id='167A4925F5'></tfoot></center><abbr id='167A4925F5'><dir id='167A4925F5'><tfoot id='167A4925F5'></tfoot><noframes id='167A4925F5'>

    • <optgroup id='167A4925F5'><strike id='167A4925F5'><sup id='167A4925F5'></sup></strike><code id='167A4925F5'></code></optgroup>
        1. <b id='167A4925F5'><label id='167A4925F5'><select id='167A4925F5'><dt id='167A4925F5'><span id='167A4925F5'></span></dt></select></label></b><u id='167A4925F5'></u>
          <i id='167A4925F5'><strike id='167A4925F5'><tt id='167A4925F5'><pre id='167A4925F5'></pre></tt></strike></i>

          Home / explore / leisure time

          leisure time


          leisure time

          author:comprehensive    Page View:9
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In